HCPCS code J9277: Pembrolizumab injection, with hyaluronidase, per 1 mg2026 Medicare rate & RVUs in Louisiana
Reports the pembrolizumab and berahyaluronidase alfa-pmph combination given by subcutaneous injection for cancer treatment, measured per 1 mg of pembrolizumab.
CMS doesn’t publish an office rate for J9277 in Louisiana.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9277 covers
This code identifies a subcutaneous cancer immunotherapy product combining pembrolizumab, an immune checkpoint inhibitor, with berahyaluronidase alfa-pmph. It is used in treatment regimens for cancers for which pembrolizumab is selected. Oncology practices and infusion centers typically report the drug for an administered dose; it is not the code for the injection-administration service itself.
CMS assigns this HCPCS Level II code physician fee schedule status E, meaning it is excluded from the physician fee schedule. When Medicare covers the drug, payment is under another method: CMS classifies it as a Part B drug generally paid using the quarterly Average Sales Price drug pricing files. Coverage is left to the Medicare contractor's judgment. Each billing unit represents 1 mg of pembrolizumab; report units based on the pembrolizumab amount administered.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9277 pays more and less in Louisiana
| Payment locality | Office | Facility |
|---|---|---|
| New Orleans, LA | Unavailable | Unavailable |
| Rest of Louisiana | Unavailable | Unavailable |
How the J9277 rate is calculated
Each of J9277’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9277
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9277
J9277 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9277
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9277 isn’t priced in this setting.
J9277 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9271PembrolizumabPer 1 mg
- Both codes involve pembrolizumab, but J9277 identifies the combination with berahyaluronidase alfa-pmph for subcutaneous injection; J9271 identifies pembrolizumab for intravenous administration.
- J9289Nivolumab-hyaluronidasePer 2 mg
- J9289 identifies nivolumab with hyaluronidase, not pembrolizumab. The drugs have distinct treatment indications and are not interchangeable solely because both are subcutaneous formulations.
- J9272Dostarlimab injectionPer 10 mg
- J9272 is dostarlimab, a different immunotherapy drug. Select the code for the drug actually administered, not by therapeutic class alone.
J9277 billing questions
How is J9277 different from J9271?
J9277 identifies pembrolizumab combined with berahyaluronidase alfa-pmph for subcutaneous use. J9271 identifies pembrolizumab without that combination product, used for intravenous administration.
Does J9277 include the administration service?
No. J9277 reports the drug quantity; report the administration service separately when appropriate.
How many units should be reported?
One unit represents 1 mg of pembrolizumab. Calculate the units from the pembrolizumab amount administered and retain documentation supporting that amount.
What is J9277's Medicare payment status?
CMS assigns status E, excluding the code from the physician fee schedule. When Medicare covers the drug, it generally pays through the Part B drug method using CMS's quarterly ASP files.
Does Medicare cover J9277?
Coverage is left to the Medicare contractor's judgment. The code's physician fee schedule status does not itself determine coverage.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9277 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist